Cargando…
Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines
Stimulant medication and behaviour therapy are the most often applied and accepted treatments for Attention-Deficit/Hyperactivity-Disorder (ADHD). Here we explore where the non-pharmacological clinical intervention known as neurofeedback (NFB), fits on the continuum of empirically supported treatmen...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250955/ https://www.ncbi.nlm.nih.gov/pubmed/32206963 http://dx.doi.org/10.1007/s10484-020-09455-2 |
_version_ | 1783538862515027968 |
---|---|
author | Arns, Martijn Clark, C. Richard Trullinger, Mark deBeus, Roger Mack, Martha Aniftos, Michelle |
author_facet | Arns, Martijn Clark, C. Richard Trullinger, Mark deBeus, Roger Mack, Martha Aniftos, Michelle |
author_sort | Arns, Martijn |
collection | PubMed |
description | Stimulant medication and behaviour therapy are the most often applied and accepted treatments for Attention-Deficit/Hyperactivity-Disorder (ADHD). Here we explore where the non-pharmacological clinical intervention known as neurofeedback (NFB), fits on the continuum of empirically supported treatments, using standard protocols. In this quantitative review we utilized an updated and stricter version of the APA guidelines for rating ‘well-established’ treatments and focused on efficacy and effectiveness using effect-sizes (ES) and remission, with a focus on long-term effects. Efficacy and effectiveness are compared to medication and behaviour therapy using benchmark studies. Only recent systematic reviews and meta-analyses as well as multi-centre randomized controlled trials (RCT’s) will be included. Two meta-analyses confirmed significant efficacy of standard neurofeedback protocols for parent and teacher rated symptoms with a medium effect size, and sustained effects after 6–12 months. Four multicenter RCT’s demonstrated significant superiority to semi-active control groups, with medium-large effect sizes end of treatment or follow-up and remission rates of 32–47%. Effectiveness in open-label studies was confirmed, no signs of publication bias were found and no significant neurofeedback-specific side effects have been reported. Standard neurofeedback protocols in the treatment of ADHD can be concluded to be a well-established treatment with medium to large effect sizes and 32–47% remission rates and sustained effects as assessed after 6–12 months. |
format | Online Article Text |
id | pubmed-7250955 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-72509552020-06-04 Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines Arns, Martijn Clark, C. Richard Trullinger, Mark deBeus, Roger Mack, Martha Aniftos, Michelle Appl Psychophysiol Biofeedback Article Stimulant medication and behaviour therapy are the most often applied and accepted treatments for Attention-Deficit/Hyperactivity-Disorder (ADHD). Here we explore where the non-pharmacological clinical intervention known as neurofeedback (NFB), fits on the continuum of empirically supported treatments, using standard protocols. In this quantitative review we utilized an updated and stricter version of the APA guidelines for rating ‘well-established’ treatments and focused on efficacy and effectiveness using effect-sizes (ES) and remission, with a focus on long-term effects. Efficacy and effectiveness are compared to medication and behaviour therapy using benchmark studies. Only recent systematic reviews and meta-analyses as well as multi-centre randomized controlled trials (RCT’s) will be included. Two meta-analyses confirmed significant efficacy of standard neurofeedback protocols for parent and teacher rated symptoms with a medium effect size, and sustained effects after 6–12 months. Four multicenter RCT’s demonstrated significant superiority to semi-active control groups, with medium-large effect sizes end of treatment or follow-up and remission rates of 32–47%. Effectiveness in open-label studies was confirmed, no signs of publication bias were found and no significant neurofeedback-specific side effects have been reported. Standard neurofeedback protocols in the treatment of ADHD can be concluded to be a well-established treatment with medium to large effect sizes and 32–47% remission rates and sustained effects as assessed after 6–12 months. Springer US 2020-03-23 2020 /pmc/articles/PMC7250955/ /pubmed/32206963 http://dx.doi.org/10.1007/s10484-020-09455-2 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Arns, Martijn Clark, C. Richard Trullinger, Mark deBeus, Roger Mack, Martha Aniftos, Michelle Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title | Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title_full | Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title_fullStr | Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title_full_unstemmed | Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title_short | Neurofeedback and Attention-Deficit/Hyperactivity-Disorder (ADHD) in Children: Rating the Evidence and Proposed Guidelines |
title_sort | neurofeedback and attention-deficit/hyperactivity-disorder (adhd) in children: rating the evidence and proposed guidelines |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7250955/ https://www.ncbi.nlm.nih.gov/pubmed/32206963 http://dx.doi.org/10.1007/s10484-020-09455-2 |
work_keys_str_mv | AT arnsmartijn neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines AT clarkcrichard neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines AT trullingermark neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines AT debeusroger neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines AT mackmartha neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines AT aniftosmichelle neurofeedbackandattentiondeficithyperactivitydisorderadhdinchildrenratingtheevidenceandproposedguidelines |